Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Real-time Estimate Cboe BZX  -  08:51 2022-12-09 am EST
176.39 USD   -0.46%
12/07Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BU
12/07Johnson & Johnson : to Participate in the 41st Annual J.P. Morgan Healthcare Conference
PU
12/07Johnson & Johnson - Tackling Health Disparities Through Empowerment, Partnership and Scholarship
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson Says Planned Consumer Health Company to Be Named Kenvue

09/28/2022 | 08:35am EST


ę MT Newswires 2022
All news about JOHNSON & JOHNSON
12/07Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BU
12/07Johnson & Johnson : to Participate in the 41st Annual J.P. Morgan Healthcare Conference
PU
12/07Johnson & Johnson - Tackling Health Disparities Through Empowerment, Partnership and Sc..
AQ
12/07GSK, Pfizer, Sanofi Breathe Sigh Of Relief After US Court Tosses Lawsuits On Zantac Can..
MT
12/06Major Pharma Companies to Remain Defensive Through at least H1 2023 Amid M&As, New Prod..
MT
12/06Morgan Stanley Trims Price Target on Johnson & Johnson to $176 From $178, Maintains Equ..
MT
12/05Johnson & Johnson : Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel ..
PU
12/05Yumanity Therapeutics to Pay Special Cash Dividend Related to Planned Asset Sale, Kinet..
MT
12/05Johnson & Johnson's Janssen Global Services Unit Says No Plans to Bid for Horizon Thera..
MT
12/03Johnson & Johnson : Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel ..
PU
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 039 M - -
Net income 2022 20 677 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 22,3x
Yield 2022 2,47%
Capitalization 463 B 463 B -
EV / Sales 2022 4,76x
EV / Sales 2023 4,54x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 177,20 $
Average target price 181,64 $
Spread / Average Target 2,50%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.57%463 286
ELI LILLY AND COMPANY34.66%353 267
ABBVIE INC.22.59%293 450
PFIZER, INC.-14.92%290 657
NOVO NORDISK A/S22.08%287 434
MERCK & CO., INC.44.64%281 049